Drug Detail

Information about Dovitinib

Generic Name	Dovitinib
IND	TKI258
Brand Name (US)
Manufacturer	Novartis
Drug Type	Tyrosine Kinase Inhibitor
Delivery	Oral
Approval Status	Phase 3
Indications	Renal cell carcinoma (RCC)
Overall Strategy	KIT Protein Based
Strategy	Block KIT + Block blood vessel growth
Drug Category	KIT/PDGFRA inhibitor+ VEGF inhibitor (TKI)

Dovitinib is an oral multi-tyrosine kinase inhibitor in phase III trials for renal cell carcinoma and in phase II trials for other indications. In addition to inhibiting KIT and VEGF receptors, it also inhibits several receptors in the fibroblast growth factor receptor (FGFR) family. FGFR receptors, like VEGF receptors are involved in angiogenesis.